Sort   by:  
 Page size 
MetabolomicsLow-Protein Diet Enhances Anti-Tumor Immunity in Pancreatic Cancer through Microbiota-Derived Uridine Diphosphate-Galactose
Low-protein diets (LPD) have been linked to improved metabolic health, but their role in pancreatic ductal adenocarcinoma (PDAC) immunotherapy remains unclear. Here we show that an LPD suppresses PDAC progression in male mice by remodeling the gut microbiota and activating anti-tumor immunity. LPD p...
2026-07-09 | MTBLS14989 | MetaboLights
MetabolomicsPharmacological Targeting of ALDH1a2 in Dendritic Cells Enhances Antigen Presentation, T Cell Activation and Anti-tumor immunity
Dendritic cell (DC) vaccines have been proposed as cancer immunotherapies due to their role as crucial antigen-presenting cells that regulate T cell functions. Despite considerable efforts to optimize ex vivo priming of DCs, DC vaccines have rarely been successful, suggesting the presence of unknown...
2025-11-03 | MTBLS10389 | MetaboLights
MetabolomicsMitochondrial respiration in B lymphocytes is essential for humoral immunity by controlling flux of the TCA cycle

To elucidate the function of oxidative phosphorylation (OxPhos) during B-cell differentiation we employ CD23Cre-driven expression of the dominant-negative K320E mutant of the mitochondrial helicase Twinkle (DNT). DNT-expression depletes mitochondrial DNA during B cell maturation, reduces the abun...

2026-08-21 | MTBLS4647 | MetaboLights
ProteomicsTumor-expressed SPPL3 supports innate anti-tumor immune responses
The development of an effective anti-tumor response relies on the synergistic actions of various immune cells that recognize tumor cells via distinct receptors. Tumors, however, often manipulate receptor-ligand interactions to evade recognition by the immune system. Recently, we highlighted the role...
ORGANISM(S): Homo sapiens (Human) 
2025-09-30 | PXD056501 | Pride
Sppl3 Cd8 t-cells Anti-tumor response B3gnt5 
ProteomicsNATCANCER-A16341B 1 2 iNV GOV 3 4GOV
Oncolytic viruses (OVs) are replication-competent viruses that selectively infect tumor cells and induce anti-tumor responses. However, systemic delivery is limited by neutralizing antibodies and poor intratumoral bioavailability. We developed iNV-GOV, a tumor-targeted, low-immunogenic platform that...
ORGANISM(S): Homo sapiens (Human) 
2025-10-03 | PXD067837 | Pride
Inv gov and gov 
GenomicsIrinotecan activates anti-tumor immunity in CT26 tumor cells
Irinotecan activates anti-tumor immunity in CT26 tumor cells
PRJNA1027843 | ENA
GenomicsIrinotecan activates anti-tumor immunity in HCT116 tumor cells
Irinotecan activates anti-tumor immunity in HCT116 tumor cells
PRJNA1030009 | ENA
MetabolomicsPolyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells

In cancer, metabolic changes and uncontrolled tumor growth alter nutrient availability, impacting antitumor immune responses. Regulatory T (Treg) cells are a subset of T cells with immunosuppressive properties that has been found to additionally possess the ability to control tissue homeostasis a...

2025-07-24 | MTBLS12633 | MetaboLights
GenomicsFTO degradation targeting enhances anti-tumor immunity
FTO degradation targeting enhances anti-tumor immunity
PRJNA1053378 | ENA
GenomicsGut-Brain Axis Regulates Liver Anti-Tumor Immunity
Gut-Brain Axis Regulates Liver Anti-Tumor Immunity
PRJNA1065314 | ENA
Sort   by:  
 Page size